{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:17Z","timestamp":1792831037674,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005329","name":"Guizhou Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["Qiankehe-Basic-ZK[2021]-General 556"],"award-info":[{"award-number":["Qiankehe-Basic-ZK[2021]-General 556"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110561","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:59:19Z","timestamp":1790146759000},"page":"110561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Indole-based peptidomimetic maleimides as SARS-CoV-2 Mpro inhibitor scaffolds compatible with reversible covalent inhibition: Warhead optimization and broad in vitro antiviral activity"],"prefix":"10.1016","volume":"183","author":[{"given":"Pengyao","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjie","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110561_bb0005","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1021\/acsmedchemlett.2c00349","article-title":"Oral nonpeptidic, noncovalent triazine coronavirus main protease inhibitors for treating COVID-19","volume":"13","author":"Chia","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110561_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110561_bb0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/biom14070797","article-title":"Inhibitors of SARS-CoV-2 main protease (Mpro) as anti-coronavirus agents","volume":"14","author":"Zag\u00f3rska","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110561_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112559","article-title":"Fight against novel coronavirus: a perspective of medicinal chemists","volume":"201","author":"Amin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0025","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001558","article-title":"Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19","volume":"102","author":"Roe","year":"2021","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.bioorg.2026.110561_bb0030","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110561_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110561_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04743","article-title":"Molecular biology of coronaviruses: current knowledge","volume":"6","author":"Artika","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2026.110561_bb0045","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.apsb.2021.06.016","article-title":"Recent advances in developing small-molecule inhibitors against SARS-CoV-2","volume":"12","author":"Xiang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110561_bb0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biom11040607","article-title":"SARS-CoV-2 M(pro): a potential target for peptidomimetics and small-molecule inhibitors","volume":"11","author":"Citarella","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110561_bb0055","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110561_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2026.117791","article-title":"From 2020 to 2025: comprehensive review decoding novel structural inhibitors for M(pro) of SARS-CoV-2","volume":"248","author":"Zhang","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110561_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110561_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118247","article-title":"Recent breakthroughs in synthetic small molecules targeting SARS-CoV-2 M(pro) from 2022 to 2024","volume":"128","author":"Braconi","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13543776.2025.2588773","article-title":"A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020\u2013present)","volume":"36","author":"Mik","year":"2026","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110561_bb0080","doi-asserted-by":"crossref","first-page":"2460045","DOI":"10.1080\/14756366.2025.2460045","article-title":"Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds","volume":"40","author":"Atatreh","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (M(pro)): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.bioorg.2026.110561_bb0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110561_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114803","article-title":"Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen","volume":"244","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0100","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110561_bb0105","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","article-title":"Deuremidevir and simnotrelvir-ritonavir for the treatment of COVID-19","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2026.110561_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117531","article-title":"Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: design, synthesis, biological evaluation, and structure-activity relationships exploration","volume":"96","author":"Zhang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115487","article-title":"Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M(pro))","volume":"257","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0120","doi-asserted-by":"crossref","first-page":"12760","DOI":"10.1021\/acs.jmedchem.4c00739","article-title":"Discovery of novel nonpeptidic and noncovalent small molecule 3CL(pro) inhibitors as anti-SARS-CoV-2 drug candidate","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0125","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110561_bb0130","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3390\/ijms23073507","article-title":"Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease","volume":"23","author":"M\u00f3ty\u00e1n","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110561_bb0135","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1039\/D2MD00344A","article-title":"Advances in research on 3C-like protease (3CL(pro)) inhibitors against SARS-CoV-2 since 2020","volume":"14","author":"Chen","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0150","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate COVID-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110561_bb0155","doi-asserted-by":"crossref","first-page":"17124","DOI":"10.1021\/acs.jmedchem.4c00656","article-title":"Peptidomimetic analogues act as effective inhibitors against SARS-CoV-2 by blocking the function of cathepsin L","volume":"67","author":"Deng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0160","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: Progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110561_bb0170","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0175","doi-asserted-by":"crossref","first-page":"21095","DOI":"10.1021\/acs.jmedchem.5c02784","article-title":"The same and not the same: discovery of S-892216, a second-generation nonpeptidic covalent 3CL protease inhibitor for oral COVID-19 therapeutics","volume":"68","author":"Stauffer","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0180","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.5c02360","article-title":"Discovery of EGT710, an oral nonpeptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor","volume":"69","author":"Papillon","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/jacsau.5c01178","article-title":"Structure-based design of covalent SARS-CoV-2 main protease inhibitors targeting the nirmatrelvir-resistant E166 mutants","volume":"6","author":"Cai","year":"2026","journal-title":"JACS Au"},{"key":"10.1016\/j.bioorg.2026.110561_bb0190","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.1021\/acs.jmedchem.2c01716","article-title":"Discovery and crystallographic studies of nonpeptidic piperazine derivatives as covalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0195","doi-asserted-by":"crossref","first-page":"21099","DOI":"10.1021\/acs.jmedchem.5c00754","article-title":"Discovery of the clinical candidate S-892216: a second-generation of SARS-CoV-2 3CL protease inhibitor for treating COVID-19","volume":"68","author":"Unoh","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1021\/acsbiomedchemau.4c00109","article-title":"Exploring possible drug-resistant variants of SARS-CoV-2 main protease (M(pro)) with noncovalent preclinical candidate, Mpro61","volume":"5","author":"Kenneson","year":"2025","journal-title":"ACS Bio. Med. Chem. Au"},{"key":"10.1016\/j.bioorg.2026.110561_bb0205","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2026.110561_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128732","article-title":"Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors","volume":"66","author":"Hicks","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110561_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (nirmatrelvir\/ritonavir): a new approach to COVID-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110561_bb0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","article-title":"Small molecules in the treatment of COVID-19","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110561_bb0225","doi-asserted-by":"crossref","first-page":"eadl4013","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110561_bb0230","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/cid\/ciae615","article-title":"Independent FDA analyses of nirmatrelvir\/ritonavir resistance in the phase 2\/3 trials EPIC-HR and EPIC-SR","volume":"80","author":"Rawson","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110561_bb0235","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 resistance after antiviral treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bioorg.2026.110561_bb0240","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110561_bb0245","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.04068-24","article-title":"Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50","volume":"16","author":"Zvornicanin","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.bioorg.2026.110561_bb0250","doi-asserted-by":"crossref","first-page":"18478","DOI":"10.1021\/acs.jmedchem.4c01781","article-title":"Effects of SARS-CoV-2 main protease mutations at positions L50, E166, and L167 rendering resistance to covalent and noncovalent inhibitors","volume":"67","author":"Kovalevsky","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0255","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/molecules25071615","article-title":"Role of indole scaffolds as pharmacophores in the development of anti-lung cancer agents","volume":"25","author":"Dhuguru","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110561_bb0260","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1021\/acs.jmedchem.1c00628","article-title":"Self-masked aldehyde inhibitors: a novel strategy for inhibiting cysteine proteases","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0265","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0270","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1021\/acs.jmedchem.0c02258","article-title":"Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2","volume":"65","author":"Dai","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0275","doi-asserted-by":"crossref","first-page":"10823","DOI":"10.1021\/acs.jmedchem.4c03024","article-title":"Development of orally bioavailable octahydroindole-based peptidomimetic derivative as a broad-spectrum inhibitor against HCoV-OC43 and SARS-CoV-2","volume":"68","author":"Hu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0280","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1021\/acs.jmedchem.5b01013","article-title":"Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease","volume":"58","author":"Zhai","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110561_bb0285","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/ja983494x","article-title":"Electrophilicity index","volume":"121","author":"Parr","year":"1999","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110561_bb0290","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1039\/D3SC05595G","article-title":"What defines electrophilicity in carbonyl compounds","volume":"15","author":"Bickelhaupt","year":"2024","journal-title":"Chem. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:58:41Z","timestamp":1792828721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":58,"alternative-id":["S0045206826010977"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110561","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indole-based peptidomimetic maleimides as SARS-CoV-2 Mpro inhibitor scaffolds compatible with reversible covalent inhibition: Warhead optimization and broad in vitro antiviral activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110561"}}